1. Home
  2. KNSA vs HMN Comparison

KNSA vs HMN Comparison

Compare KNSA & HMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • HMN
  • Stock Information
  • Founded
  • KNSA 2015
  • HMN 1945
  • Country
  • KNSA United Kingdom
  • HMN United States
  • Employees
  • KNSA N/A
  • HMN N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • HMN Property-Casualty Insurers
  • Sector
  • KNSA Health Care
  • HMN Finance
  • Exchange
  • KNSA Nasdaq
  • HMN Nasdaq
  • Market Cap
  • KNSA 1.6B
  • HMN 1.7B
  • IPO Year
  • KNSA 2018
  • HMN 1991
  • Fundamental
  • Price
  • KNSA $23.09
  • HMN $42.64
  • Analyst Decision
  • KNSA Strong Buy
  • HMN Hold
  • Analyst Count
  • KNSA 6
  • HMN 3
  • Target Price
  • KNSA $37.17
  • HMN $44.50
  • AVG Volume (30 Days)
  • KNSA 684.1K
  • HMN 200.5K
  • Earning Date
  • KNSA 04-22-2025
  • HMN 05-07-2025
  • Dividend Yield
  • KNSA N/A
  • HMN 3.28%
  • EPS Growth
  • KNSA N/A
  • HMN 127.61
  • EPS
  • KNSA N/A
  • HMN 2.48
  • Revenue
  • KNSA $423,239,000.00
  • HMN $1,595,200,000.00
  • Revenue This Year
  • KNSA $37.21
  • HMN $9.64
  • Revenue Next Year
  • KNSA $1.38
  • HMN $6.00
  • P/E Ratio
  • KNSA N/A
  • HMN $17.19
  • Revenue Growth
  • KNSA 56.60
  • HMN 6.92
  • 52 Week Low
  • KNSA $16.56
  • HMN $31.81
  • 52 Week High
  • KNSA $28.15
  • HMN $43.53
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 60.12
  • HMN 59.25
  • Support Level
  • KNSA $22.62
  • HMN $40.66
  • Resistance Level
  • KNSA $23.42
  • HMN $43.28
  • Average True Range (ATR)
  • KNSA 0.75
  • HMN 0.84
  • MACD
  • KNSA -0.01
  • HMN 0.09
  • Stochastic Oscillator
  • KNSA 68.88
  • HMN 80.55

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About HMN Horace Mann Educators Corporation

Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The company uses several former teachers in its salesforce. Its segments include Property and Casualty, Supplemental & Group Benefits, Life & Retirement, and Corporate and Other.

Share on Social Networks: